J. P. Jonas

HPB @ University Zurich I PhD

[J. P. Jonas @TELL_JPJONAS]

What an honor: fellowship graduation amongst the ISLS faculty during the #isls2023 in #zurich 🤩

[Philip C. Müller @PhilipMueller_1]

🇨🇭First day of the 5th Congress of International Advanced HPB Surgery in Zürich

💥Highlights💥
Robot&laparoscopic live surgery from Modena& Paris

Workshops on machine perfusion&IOUS

Huge enthusiasm for Robotic liver surgery

#isls2023 @ISLSSymposium

[J. P. Jonas @TELL_JPJONAS]

Congrats to this unique opportunity! Go #TELLStarlinger

[Patrick Starlinger_TELL International @TELL_Starlinger]

Please join me in celebrating Dr. Ammann for being awarded the #IHPBA Kenneth Warren Fellowship to join our Lab at #MayoClinic - thank you #IHPBA for this outstanding support to understand the relevance of circulating metabolites in liver regeneration #TELL

[J. P. Jonas @TELL_JPJONAS]

Do you have the same clinical experience?

🔥 better path response and RFS for potentially resectable mCRC with preOP VEGF chemo combination compared to EGFR 💉

https://t.co/ziMZJeMzw2 #mdpicancers via @Cancers_MDPI @tgruenberger

[J. P. Jonas @TELL_JPJONAS]

@PipeCabreraV @pferrada1 @SWexner @almagoch @Cirbosque @MISIRG1 @drdevirgilio @rbarbosa91 @DissanaikeMD Fitz

[J. P. Jonas @TELL_JPJONAS]

@ThomasHankMD @motazqadan @AnnalsofSurgery @UllaKlaiber Our yesterday’s Whipple was aborted due to persistent tumor involvement to proper hepatic artery after 12x FOLFOXIRI as NAT.. R0 not feasible

Thanks for the interesting data confirming R0 still as best outcome for the patient

[European Society of Surgical Oncology (ESSO) @ESSOnews]

🔜ESSO Webinar on New Perspectives in the Treatment of #PNETS and the Role of #Theranostics - A #MultidisciplinaryApproach
🗓️ 17 May 2023
🕖 7pm to 8pm CET
��� https://t.co/bc1epYMCr5
@spartelli @SStattner @Ja_Capdevila @ProfKHerrmann @ITM_Radiopharma
#SurgicalOncology

[J. P. Jonas @TELL_JPJONAS]

Sunday night read on the way 🚎to a procurement 🏥 about Hemodynamic Changes After Liver Transplant with pretty cool algorithm to assess flow changes to the graft 😷🇨🇭https://t.co/4MmQH5Bk4i direct/Fulltext/2022/09000/Understanding_Local_Hemodynamic_Changes_After.10.aspx

[Giovanni Marchegiani @Gio_Marchegiani]

Mucinous cystic neoplasms of the pancreas 🐡 are they all surgical candidates ?!

🥑 Size < 4cm, normal CA19.9 and no mural nodules exclude invasive cancer

🪡 Pro surgery advocates cancer prevention and usually MIS

Your practice ?!

https://t.co/ASjgRZkerw

[David Pereyra @TELLpereyra]

We’re thrilled and excited about the opportunity to initiate a new project on post-transplant #liver and bile duct regeneration 🧫🔬👨‍🔬. Thank you to the transplant platform @MedUni_Wien for the support!

[Austrian Association of HPB Surgery @aahpbs]

Great talks🎙and discussions 💬 at the first AAHPBS Meeting & HPB Masterclass @ Clinic Favoriten Vienna 😷🔪🥢
Many thanks to all participants for joining us, in particular our international guests @iisifrigerio and Prof. Siriwardena, it was really a pleasure having you with us!

[Miguel E. Tobon @MiguelTobonL]

#HPBWeekly Small study but frequently asked question. What level of CA 19-9 matters and how much should it drop after NAT for PDAC. Here a Pre-treatment CA19-9 >500 U/mL, the CA19-9 decrease ≤80% was strongly associated with poor survival https://t.co/up2E6sdnuR

[J. P. Jonas @TELL_JPJONAS]

Congrats @TELLpereyra ! @TELL_Starlinger going strong

[David Pereyra @TELLpereyra]

Honoured to have received the Award of Excellence from the Austrian Federal Ministry for Education, Science and Research for my dissertation! Special thanks to ⁦⁦@TELL_Starlinger⁩ and ⁦⁦@PlateletVienna⁩ for your guidance and support! https://t.co/iJOw916HIj

[Mayo Clinic Department of Surgery @MayoClinicSurg]

A team of surgery & oncology experts at @MayoClinic are using hepatic artery infusion pump chemotherapy in select patients, providing a liver-directed treatment option for patients who previously had none. Learn more: https://t.co/P5zl1rBRWO @MayoCancerCare @ThielsCA @drsuswarner

[Dr. Shubham Pant @DrShubhamPant]

Zanidatamab (Bispecific targeting HER2) for HER2-positive cancers including
#BiliaryTractCancer ORR: ➡️ 38%; DCR ➡️ 62%
#Colorectalcancer ORR: ➡️ 38%; DCR ➡️ 77%

@MDAndersonNews @curecc @rachnatshroff @JavleMilind @CathyEngMD @GIcancerDoc

https://t.co/k53s1MeAur

[J. P. Jonas @TELL_JPJONAS]

Serge Evrard giving the tour of Bordeaux at ESSO 41. > 800 attendees discussing surgonc #ESSO41 #Bordeaux

[Patrick Starlinger_TELL International @TELL_Starlinger]

Probably nothing more satisfying for a translational researcher - this is for everyone who believes that we need to get better at preoperative liver function testing @rna_ami @MayoClinicSurg @hpb_so @MedUni_Wien @AHPBA https://t.co/qOyeqssbe0

[J. P. Jonas @TELL_JPJONAS]

@TELL_Starlinger @TELL_Santol @TELLpereyra Congrats Tell_Starlinger crew 🫡

[The Innovation | Medicine @Innov_Medicine]

When robots draw blood

[J. P. Jonas @TELL_JPJONAS]

Moderate fluid resuscitation for acute pancreatitis with less fluid overload the way to go? 📖 @DeMadeira @NEJM

[Giovanni Marchegiani @Gio_Marchegiani]

Aggressive 🤜🤛 moderate fluid resuscitation in acute pancreatitis

🇪🇸 🇮🇳 RCT in @NEJM by @DeMadaria with fluid overload as safety outcome

🚿 Early Aggressive resuscitation higher incidence of fluid overload without improvement in clinical outcomes

https://t.co/UpwVkIj4nX